Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3-Reference-Cited by-同舟云学术

Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3

Published:2023 Issue:2 Volume:34 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Lee Jung-Yun¹^ORCID,Lee Yoo-Young²^ORCID,Park Jeong-Yeol³^ORCID,Shim Seung-Hyuk⁴^ORCID,Kim Se Ik⁵^ORCID,Kong Tae-Wook⁶^ORCID,Lim Chul Kwon⁷^ORCID,Cho Hyun Woong⁸^ORCID,Suh Dong Hoon⁹^ORCID

Affiliation:

1. Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.

2. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

3. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

4. Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.

5. Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea.

6. Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.

7. Department of Obstetrics and Gynecology, Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea.

8. Department of Obstetrics and Gynecology, Guro Hospital, Korea University College of Medicine, Seoul, Korea.

9. Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.

Publisher

XMLink

Subject

Obstetrics and Gynecology,Oncology,General Medicine

Link

https://ejgo.org/pdf/10.3802/jgo.2023.34.e51

Reference79 articles.

1. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

2. LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

3. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

4. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab

5. Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers;Cancers;2024-09-05

2. Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer;ESMO Open;2024-09

3. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer;Journal of Translational Medicine;2024-08-21

4. Sotorasib versus docetaxel: evidence supporting CodeBreaK 200;The Lancet Oncology;2024-08

5. Past and present: a bibliometric study on the treatment of recurrent ovarian cancer;Frontiers in Pharmacology;2024-07-30